Trial Profile
Single-center, Open Label Trial of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Neuromyelitis optica
- Focus Therapeutic Use
- 15 Oct 2018 Status changed from active, no longer recruiting to completed.
- 24 Sep 2016 New trial record